Arkadios Wealth Advisors Acquires Shares of 8,599 Hims & Hers Health, Inc. $HIMS

Arkadios Wealth Advisors acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,599 shares of the company’s stock, valued at approximately $429,000.

Several other hedge funds have also made changes to their positions in the company. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter valued at approximately $29,000. New York Life Investment Management LLC purchased a new stake in shares of Hims & Hers Health in the second quarter valued at $963,000. United Capital Management of KS Inc. lifted its holdings in shares of Hims & Hers Health by 1,660.0% in the second quarter. United Capital Management of KS Inc. now owns 189,274 shares of the company’s stock valued at $9,435,000 after purchasing an additional 178,520 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Hims & Hers Health by 26.5% in the second quarter. Teacher Retirement System of Texas now owns 33,018 shares of the company’s stock valued at $1,646,000 after purchasing an additional 6,925 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of Hims & Hers Health by 62.4% in the second quarter. Y Intercept Hong Kong Ltd now owns 104,600 shares of the company’s stock valued at $5,214,000 after purchasing an additional 40,186 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of HIMS opened at $42.67 on Wednesday. The firm has a market cap of $9.64 billion, a PE ratio of 79.02, a PEG ratio of 3.07 and a beta of 2.20. The firm’s 50 day moving average price is $51.36 and its 200 day moving average price is $50.84. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a twelve month low of $19.15 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.09 earnings per share for the quarter, meeting the consensus estimate of $0.09. The firm had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 26.48%. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 660,000 shares of the firm’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Chi sold 13,749 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $694,324.50. Following the transaction, the insider owned 297,139 shares in the company, valued at approximately $15,005,519.50. This trade represents a 4.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,372,271 shares of company stock worth $71,014,785 over the last three months. Corporate insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

HIMS has been the subject of several research analyst reports. KeyCorp initiated coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating for the company. UBS Group set a $32.00 price target on shares of Hims & Hers Health in a research report on Tuesday. Canaccord Genuity Group reissued a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. Zacks Research downgraded shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Finally, Truist Financial cut their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Reduce” and an average price target of $43.75.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.